FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.
Servier drug Tibsovo is now approved for treating advanced cases of myelodysplastic syndrome that have an IDH1 mutation. It’s the first approval of a targeted therapy for this type of cancer.
China - The partner of CStone Pharmaceuticals Servier announced that they will showcase new data for TIBSOVO at the 2023 American Society of Clinical Oncology Annual Meeting and the European. | May 29, 2023
Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in EuropeThe positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA)